Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL869856 | 0.70 | ENPP1 (0.51) | — | |
| Fluorouracil SCHEMBL6242294 | 0.69 | LMNA (0.59) | CRBNDDB1ALDH1A1LMNA | |
| Benzoyl Peroxide SCHEMBL4370687 | 0.68 | F2 (0.52) | CRBNDDB1ALDH1A1LMNA | |
| Ribose (Furanose) SCHEMBL2406693 | 0.66 | SLC28A1 (0.63) | — | |
| SCHEMBL8377720 | 0.66 | — | — | |
| SCHEMBL8790967 | 0.61 | — | — | |
| SCHEMBL710129 | 0.61 | — | — | |
| SCHEMBL10423652 | 0.61 | — | — | |
| SCHEMBL422813 | 0.61 | — | — | |
| SCHEMBL5963506 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050255038-A1 | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof | A AND D BIOSCIENCE, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050233949-A1 | Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof | HOLICK MICHAEL F | 2005-10-20 | — | — | US | disclosed |
| WO-2003086312-A2 | CONJUGATES COMPRISING CANCER CELL SPECIFIC LIGANDS, A SUGAR AND CANCER CHEMOTHERAPEUTIC AGENTS/BORON NEUTRON CAPTURE THERAPY AGENTS, AND USES THEREOF | A & D BIOSCIENCE, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233949-A1 | Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof | CD22, HUNK, FUT4 | CRBN 1845/4885DDB1 175/4885L3MBTL1 1641/4885 |
| US-20050255038-A1 | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof | CD44, FUT5, FUT6 | CRBN 2822/4885DDB1 875/4885L3MBTL1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.